BioSeek raises $10M from Amylin Pharma for drug screening
BioSeek, a Burlingame, Calif., developer of drug-screening technologies that use human cells, raised $10 million in a third funding round from San Diego-based Amylin Pharmaceuticals. The two companies also formed a partnership in which BioSeek will screen Amylin’s collection of protein fragments, or peptides, to identify possible drugs for treating inflammatory diseases.
As part of that collaboration, BioSeek can select two of Amylin’s peptides for development in diseases outside of Amylin’s own sphere of interest. The new partnership grew out of a previous collaboration (PDF) the two companies struck last August.
The BioSeek release is here.
Next Story: BioSeek raises $10M from Amylin for drug screening
Previous Story: Arete raises $35M for cardiovascular treatments
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.